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Abstract
The aging phenotype in humans has been thoroughly studied but a detailed metabolic profiling capable of shading light on
the underpinning biological processes of longevity is still missing. Here using a combined metabonomics approach
compromising holistic 1H-NMR profiling and targeted MS approaches, we report for the first time the metabolic phenotype
of longevity in a well characterized human aging cohort compromising mostly female centenarians, elderly, and young
individuals. With increasing age, targeted MS profiling of blood serum displayed a marked decrease in tryptophan
concentration, while an unique alteration of specific glycerophospholipids and sphingolipids are seen in the longevity
phenotype. We hypothesized that the overall lipidome changes specific to longevity putatively reflect centenarians’ unique
capacity to adapt/respond to the accumulating oxidative and chronic inflammatory conditions characteristic of their
extreme aging phenotype. Our data in centenarians support promotion of cellular detoxification mechanisms through
specific modulation of the arachidonic acid metabolic cascade as we underpinned increased concentration of 8,9-EpETrE,
suggesting enhanced cytochrome P450 (CYP) enzyme activity. Such effective mechanism might result in the activation of an
anti-oxidative response, as displayed by decreased circulating levels of 9-HODE and 9-oxoODE, markers of lipid peroxidation
and oxidative products of linoleic acid. Lastly, we also revealed that the longevity process deeply affects the structure and
composition of the human gut microbiota as shown by the increased extrection of phenylacetylglutamine (PAG) and p-
cresol sulfate (PCS) in urine of centenarians. Together, our novel approach in this representative Italian longevity cohort
support the hypothesis that a complex remodeling of lipid, amino acid metabolism, and of gut microbiota functionality are
key regulatory processes marking exceptional longevity in humans.
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Introduction
The aging phenotype in humans is very heterogeneous and can
be described as a complex mosaic resulting from the interaction of
a variety of environmental, stochastic and genetic-epigenetic
variables [1] .Decades of research on aging have found hundreds
of genes [2] and many biological processes [3] that are associated
to the aging process, but at the same time, these are still based on
few targeted biological outcomes mostly lacking a general
molecular footprint which would encompass the longevity process
as a as a multi-factorial event [4]. Moreover, the identification of
biological markers specific of exceptional longevity is still on its
infancy, and their characterization could provide insights into
specific molecular mechanisms and/or biological processes of
aging. Indeed, aging appears to be characterized by an increasing
chronic, low grade inflammatory status indicated as inflamm-aging
[5,6] but centenarians, despite showing some markers of
inflammation, avoid or delay the major inflammation-driven
age-related diseases, such as cardiovascular disease (CVD),
diabetes mellitus (DM) Alzheimer disease (AD), and cancer [7].
Metabonomics is considered today a well-established system
approach to characterize the metabolic phenotype, which results
from a coordinated physiological response to various intrinsic and
extrinsic parameters including environment, drugs, dietary
patterns, lifestyle, genetics, and microbiome [8]. Recently,
metabonomics had successfully been applied to study the
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modulation of the aging processes following nutritional interven-
tions, including caloric restriction-induced metabolic changes in
mouse [9], dogs [10], and non-human primates [11]. Beyond the
insight provided by these studies, a comprehensive metabolic
phenotype of longevity in humans has not yet been reported.
Using a combined holistic nuclear magnetic resonance (NMR)
profiling in urine, targeted liquid chromatography–mass spec-
trometry (LC-MS/MS) approaches in serum, and a powerful
human model of aging and longevity (large group of subjects with
an age range of 21–111 years old) objective of this study was to
identify the molecular footprints of longevity. Highly informative
age groups are represented by centenarians (mean age 100.9 yrs),
accepted model of healthy aging and extreme longevity [12],
elderly (mean age 70 yrs), and young adults (mean age 31 yrs), all
recruited in Northern Italy. Our longevity cohort is composed
mostly by females due to reported mortality and genetic
characteristics of the Northern Italian population [13], therefore
our choice was here to have samples representative of the overall.
The elderly individuals were recruited according to strict
demographic criteria, an approach which allowed us to further
subdivide these subjects having the same chronological age on the
basis of their different familial longevity, i.e. offspring of non long-
lived parents (mean parental death age, 59.3) and offspring of
centenarians, reported to experience a better health and marked
delay in the onset of age-related diseases [14]. Moreover, a group
of subjects affected by Down ’s syndrome (DS, mean age 28 yrs)
was studied as a model of premature aging [15] in order to further
validate the identified putative metabolic signatures/biomarkers of
aging (Figure S1, Text S4, Table S15). Finally, we assessed the
associations between changes in bacterial communities’ structure
and dynamics of host metabolic patterns taking advantage of the
fact that a subgroup of young, elderly and centenarians subjects
was previously fully characterized for the composition of their
intestinal microbiota [16].
Materials and Methods
Study Design and Subjects Sampling
Overall a total of 396 subjects belonging to different age groups
were enrolled from three Italian cities (Bologna, Milan, and
Florence). The group of centenarians consisted of 143 subjects (30
males and 113 females, mean age 100.962.1 yrs) born in Italy
between the years 1900 and 1908. The elderly group is composed
of 210 centenarian’s offspring (91 males and 119 females, mean
age 7066.2 yrs) with one centenarian parent born in Italy in the
1900–1908 yrs, and 73 age-matched offspring of non long-lived
parents (37 males and 36 females, mean age 7064.8 years) with
both parents born in Italy in the same birth cohort of centenarians
but dead before the average life expectancy at 15 years of age (67
years for the father and 72 years for the mother) according to
Italian mortality tables. The group of young individuals includes
21 subjects (11 males and 10 females, mean age 30.665 yrs).
Subjects with Down’s syndrome (DS) were also recruited. In
particular, a total of 51 DS (26 males, 25 females) of different age,
from 12 to 70 years (mean age 28.54613.0), were enrolled. From a
karyotype point of view, 38 were free trisomy, 7 were mosaic, 3
translocations and 3 were diagnosed as DS clinically. The study
protocol was approved by the Ethical Committee of Sant’Orsola-
Malpighi University Hospital (Bologna, Italy). After obtaining
written informed consent, a standard questionnaire (Text S1) to
collect demographic data, anthropometric measurements, cogni-
tive and health status, clinical anamnesis, and drug use was
administrated to the subjects or to their proxy in case of DS
subjects. The health questionnaire was administered by trained
personnel and the history of major age-related diseases contrib-
uting to morbidity and mortality was accurately reported.
Overnight fasting blood samples were obtained in the morning
(between 7 and 8 a.m.). Serum was obtained after clotting and
centrifugation at 760 g for 20 min at 4uC, and immediately frozen
and stored at 280uC. The first morning urine samples were
collected in a sterile tube, and immediately stored at 280uC. Full
hematochemical and cytokines methods are reported in Supple-
mentary information (Text S2).
Untargeted serum MS metabonomics
Targeted LC-MS/MS global metabonomic approach on serum
samples from the aging cohort (Table 1) was used by combining
the Biocrates Life Sciences AbsoluteIDQTM kit for serum samples
and was based on previously published work [17,18].Well plate
preparation and sample application and extraction were carried
out according to the manufacturer’s instructions. A final volume of
10 ml of serum was loaded onto the provided 96-well plate,
containing isotopically labeled internal standards. Liquid chroma-
tography was realized on a Dionex Ultimate 3000 ultra high
pressure liquid chromatography (UHPLC) system (Dionex AG,
Olten, Switzerland) coupled to a 3200 Q TRAP mass spectrom-
eter (AB Sciex; Foster City, CA, USA) fitted with a TurboV ion
source operating in electrospray ionization (ESI) mode. Sample
extracts (20 ml) were injected two times (in positive and negative
ESI modes) via direct infusion using a gradient flow rate of 0–
2.4 min: 30 ml/min, 2.4–2.8 min: 200 ml/min, 2.9–3 min: 30 ml/
min. MS source parameters were set at: desolvation temperature
(TEM): 200uC, high voltage: 24500 V (ESI2), 5500 V (ESI+),
curtain (CUR) and nebuliser (GS1 and GS2) gases: nitrogen; 20,
40, and 50 psi; respectively, nitrogen collision gas pressure: 5
mTorr. MS/MS acquisition was realised in scheduled reaction
monitoring (SRM) mode with optimised declustering potential
values for the 163 metabolites screened in the assay. Raw data files
(Analyst software, version 1.5.1; AB Sciex, Foster City, CA, USA)
were imported into the provided analysis software MetIQ to
calculate metabolite concentrations.
Targeted serum eicosanoids analysis
A LC-MS/MS method to measure and quantify a panel of 63
inflammatory markers (eicosanoids) was developed in house.
Method was based on previously published work [17,18]. 300 ml
of serum samples from remaining available biological material
from the three age groups (Table 1) were homogenized with 10 ml
of BHT-buffer (butylated hydroxytoluene; 79.2 mg/ml PBS) using
the FastPrepH 24 system. 5 ml of the internal standard solution
(0.1 ng/ml) is added to 100 mL of plasma sample.10 ml of butylated
hydroxytoluene (0.359 mM) is added and the mixture is acidified
by adding 15 ml of citric acid (1N). A volume of 550 ml of
methanol/ethanol (1:1, v:v) was added and samples were mixed
during 15 min at 4uC before being centrifuged (3500 rpm, 10 min,
4uC). The organic phase was evaporated to dryness under constant
nitrogen flow and the residues were solubilised with 80 ml water,
followed by the addition of 20 mL of acetonitrile, before being
centrifuged at 3500 rpm for 1 min at 4uC. The supernatant was
transferred into LC-MS vials before analysis. Analyses were
carried out by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS). LC was realized on a Dionex
Ultimate 3000 ultra pressure liquid chromatography (UPLC)
system (Dionex AG, Olten, Switzerland). MS detection was
realized on a 5500 Q TRAP mass spectrometer (AB Sciex; Foster
City, CA, USA) operating in ESI mode. Gradient chromato-
graphic separation was performed on an Acquity BEH C18
column (2.16150 mm, 1.7 mm; Waters, Milford, USA). The
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injection volume was 5 ml and the column was maintained at
50uC. The mobile phase consisted of water containing 1% acetic
acid (eluent A) and acetonitrile (eluent B) at a constant flow rate set
at 450 ml/min. Gradient elution started from 20% B with a linear
increase to 50% B at 6 min, from 50% to 95% B at 13 min, hold
for 3 min at 95% B, before going back to 20% B at 16.1 min and
reequilibration of the column for additional 11 min. Analytes were
monitored in the scheduled selected reaction monitoring (sched-
uled SRM) mode provided within the Analyst software (version
1.5.1; AB Sciex, Foster City, CA, USA). All mass transitions and
MS source parameters are given in supplementary data. The SRM
detection window time was set at 120 sec with a target scan time of
0.5 sec. Nitrogen was used as curtain and desolvation gas at the
respective pressure of CUR: 20, GS1: 70, GS2: 20 (arbitrary unit).
Block source temperature was maintained at 600uC, with the
respective voltages: ISV: 24000 V, EP: 210 V, CXP: 25 V. A
15-points calibration curve was realized prior to sample analysis by
measuring different dilutions of the standard solution (0–10 ng).
Data processing was realized using Analyst software (version 1.5.1;
AB Sciex, Foster City, CA, USA). Peak area ratio of each analyte
versus its corresponding internal standard or surrogate marker was
calculated. It is worth to mention that PGJ2, PGF2a, PGE2,
PGE1, 15-oxo-HETE, 15-deoxy-D12,14-PGJ2, 6-keto PGF1a,
and 5-oxo-ETE were below their detection limit in serum samples
and therefore were not taken into account for statistical analysis.
Annotation of lipid species
LPC, Lysophosphatidylcholines; PC, Phosphatidylcholines; PC-
O, 1-O-alkyl-2-acylglycerophosphocholines; SM, Sphingomye-
lines; SM-OH, Hydroxy-Sphingomyelin. Individual lipid species
were annotated as follows: [lipid class] [total number of carbon
atoms]:[total number of double bonds]. For example, PC 34:4
reflects a phosphatidylcholine species comprising 34 carbon atoms
and 4 double bonds.
Untargeted urine metabonomics profiling
Urine metabolic profiles were measured on a Bruker Avance III
600 MHz NMR spectrometer equipped with an inverse 5 mm
cryogenic probe at 300 K (Bruker Biospin, Rheinstetten,
Germany). For each urine 1H NMR spectra were registered using
pulse sequences including a standard 1H detection with water
suppression as previously reported [59–60]. The peak assignment
to specific metabolites was achieved using an internal library of
compounds and the literature [61] and confirmed by standard
two-dimensional NMR spectroscopy (JRES, TOCSY, HSQC,
HMBC) on selected samples. Full method is reported in
Supplementary information (Text S3).
Multivariate Data Analysis
For all the analysis Multivariate Data Analysis (MVA) was
performed in several software environments. Thus, data import
and pre-processing steps for both 1H NMR and targeted MS data
were done using ‘in-house’ routines written in MATLAB (version
7.11.0, The Mathworks Inc., Natick, MA, USA). For urine
analysis full resolution 1H-NMR spectra incorporating data points
within the d 0.4–9.5 region were used for statistical multivariate
analysis excluding the water residue signal between d 4.5–6.5 [19].
In NMR data analysis OPLS-DA models were carried out by
using the SIMCA-P+ software (version 12.0, Umetrics AB, Umea˚,
Sweden). The 1H-NMR discriminant model obtained between
centenarians and elderly groups (Table S10) generated a model
with an AuROC (expressed as area under the ROC curve,
AuROC) validation error of 0.93 using again a 13.7% of the total
X variance. In NMR data analysis OPLS-DA models (Figure S2)
were carried out by using the SIMCA-P+ software (version 12.0,
Umetrics AB, Umea˚, Sweden). Targeted MS data was analyzed by
Random Forests by using the package ‘randomForest’ [20]
(http://www.R-project.org/). Spearman autocorrelation matrices
were calculated using R and corresponding graphs were produced
using the package Rgraphviz v.1.32.0. Univariate significance tests
for confirmation were also performed in R.
Urine metabotypes integration with microbiome data
The fecal microbiota of a randomly selected number of
individuals from the aging cohort (16 centenarians, 21 elderly
and 19 young) was characterized by HITChips as previously
published [16].
Results
Clinical Characteristics of the age cohort
We performed targeted liquid chromatography–mass spectrom-
etry (LC-MS/MS) in serum and nuclear magnetic resonance (1H-
NMR) profiling in urine in human model of aging and longevity,
compromising young, elderly, and centenarian individuals
(Table 1). Cohort sampling was based on availability of biofluid
samples (urine) and availability of remaining (serum) samples from
different targeted LC-MS/MS profiling applied methods assuring
proper uniform distribution among genders (elderly) and parental
longevity (centenarians’ offspring and offspring of not long living
parents). As expected, centenarians were characterized by a
number of significant differences regarding a variety of parameters
(Table S1, BMI p,0.001, HOMA p,0.001, total cholesterol
p,0.01, triglycerides p,0.05, HDL p,0.01, LDL p,0.01, A-
SAA p,0.001, and CRP p,0.001 among others) in comparison
to elderly (including offspring of centenarians and offspring of non
long-lived parents) and young subjects. In addition, centenarians
Table 1. Demographic characteristics of the recruited age cohorts.
Metabonomics Centenerians
Elderly-Offspring of
centenarians
Elderly-Offspring of
non long-lived parents Young
Serum-Untargeted LC-MS/MS: Gender,
male/female, Age, years
30/113, 100.962 (99–111) 14/32, 68.466 (56–81) 19/25, 70.766 (59–86) 11/10, 30.65 (24–40)
Serum-Quantitative LC-MS/MS Eicosanoids:
Gender, male/female, Age, years
2/10, 10162 (99–104) 11/6, 66.366 (59–74) 10/10, 73.163 (68–76) 9/9, 31.265 (25–40)
Urine-Untargeted 1H-NMR metabonomics:
Gender, male/female, Age, years
18/74, 100.962 (99–111) 91/119, 70.166 (55–88) 37/36, 70.365 (57–79) 11/10, 30.965 (24–40)
Values are presented as mean 6SD with the range in parentheses.
doi:10.1371/journal.pone.0056564.t001
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showed low prevalence of severe cognitive decline, as measured by
the Mini-Mental State Examination test (MMSE) [21].
Serum lipidome signatures of aging and longevity
To unravel comprehensive metabolic signatures of aging we
implemented targeted LC-MS/MS global metabonomic approach
on serum samples from 143 centenarians, 90 elderly and 21 young
individuals (Table 1). We performed multivariate data analysis
using Random Forest (RFTM) on pre processed semi-quantitative
data on the given 160 metabolites (amino acids, sugars, acyl-
carnitines, sphingolipids, and glycerophospholipids). Using the
variable importance feature implemented in RFTM, we uncovered
the metabolic signatures that better discriminates among the three
age groups. To assess the individual discriminant ability of each
component of the signature, we applied Wilcoxon Rank sum tests
among the age groups. While the overall concentration of
glycerolphospholipids and sphingolipids increased and decreased
depending on the fatty acid composition, we identified three
distinct metabolic patterns : (i) set of compounds that that
monotonically increased or decreased (statistically significant) with
age (Fig. 1A, Table S3), likely representing metabolic signatures of
the aging process, such as decreased concentrations of Tryptophan
(Trp), lysophospatidylcholines (LPC 18:2, LPC 20:4), increased
levels of PC 32:0 and sphingomyelins (SM 24:1, SM 16:0); (ii) a set
of compounds remaining largely unchanged until age 70 and
undergoing significant changes in centenarians (Fig. 1B, Table S3),
characterized by a complex pattern of decreased concentration in
sphingomyelins and specific glycerophospholipids (SM-OH 22:1,
LPC 18:0, SM 24:0, PC-O 34:3, PC-O 36:4, PC-O 40:1, PC 36:2)
and increased concentration in specific glycerophospholipids (PC-
O 32:1, PC-O 34:1); (iii) set of compounds which changes in the
elderly, but is remarkably similar in young subjects and
centenarians, (Fig. 1C, Table S3), putatively representing the
metabolic phenotype of longevity, characterized by an increased
concentration of specific glycerophospholipids (PC34:4, PC36:6,
PC 36:5, PC 38:4, PC 38:6, PC 40:6, PC-O 38:0, PC-O 38:6).
To further investigate the centenarian’s response to immune
and inflammatory processes we performed a quantitative LC-MS/
MS eicosanoids profiling on serum samples from a restricted
number of 12 centenarians, 37 elderly and 18 young subjects
(Table 1). Compared to elderly and young individuals, RFTM on
quantitative data displayed statistical changes in the centenarian
group, (Fig. 2) as assessed by Wilcoxon rank sum test (all
significantly regulated metabolites are listed in Table S6).
Specifically, centenarians exhibit lower concentration of 11,12-
dihydroxy-eicosatrienoic acid (11,12-DiHETrE), 9-hydroxy-octa-
decadienoic acid (9-HODE), and 9-oxo-octadecadienoic acid (9-
oxo-HODE), and increased concentrations of 15-hydroxy-eicosa-
tetraenoic acid (15-HETE), and leukotriene E4 (LTE4). Com-
pared to elderly levels of eicosapentaenoic acid (EPA) decreased
also in centenarians. Furthermore, to maximize metabolic changes
between centenarians and elderly, we applied pair-wise Multiple
Regression/Correlation (MRC) analysis between these two age
groups displaying increased serum concentration levels of 8,9-
epoxyeicosatrienoic (8,9-EET) in centenarians.
Lastly, we have reported concentration values for the selected
metabolites of interest for female and male individuals in both
global metabonomic and eicosanoids analysis. For global meta-
bonomic profiling no differences were displayed for selected
metabolites after gender separation (Tables S4, S5). For targeted
eicosanoids analysis the majority of samples represent females
individuals (Table 1), therefore the displayed statistical differences
remain when looking only in females (Tables S7), while in males,
as the number among centenarians is very low, and we report their
values with the overall metabolic changes kept (Tables S8), it is
worth to mention that this leads to limited statistical power.
Metabolic phenotypic differences within the elderly
group according to parental longevity
To identify metabolomic biomarkers capable of distinguishing
between the two subgroups (elderly offspring of centenarians and
elderly offspring of non long-lived parents), we further analyzed by
RFTM the group of elderly taking into account the age of their
parents (familial longevity, Table S2). Here, we underpinned in
centenarian’s offspring (46 subjects, average age 68.4), compared
to offspring of non long-lived parents (44 subjects, average age
70.5) (Figure 3, Table S9), higher concentrations of specific
lysophospatidylcholines (LPC 16:0, LPC 16:1, LPC 18:0, LPC
18:1, LPC 18:2), glycerophospholipids (PC-O 36:3) and two amino
acids (serine, phenylalanine). In the measured eicosanoids panel,
no metabolic differences were noted among centenarians’
offspring (17 subjects, average age 66.3) and offspring of non
long-lived parents (20 subjects, average age 73.1). No metabolic
differences in urine profiling were discerned among centenarian’s
offspring (210 subjects, average age 70.1) and offspring of non
long-lived parents (73 subjects, average age 70.3).
Metabolic signature of longevity in 1H-NMR urine profiles
mirroring changes in centenarians gut microbiota
To underpin longevity-induced changes in urine we performed
600 MHz 1H-NMR metabolic profiling on the three age-groups
(Table 1, 92 centenarians, 283 elderly and 21 young adults). We
processed the data by multivariate analysis while we applied
Orthogonal Projection on Latent Structures – Discriminant
Analysis (OPLS-DA) (Fig. S11A) on unit variance scaled data.
Interpretation of the O-PLS-DA regression coefficients (Figure
S2B) for the first latent component [19], displayed higher levels of
phenylacetylglutamine (PAG), p-cresol-sulfate (PCS), and 2-
Hydroxybenzoate (2-HB) in centenarians compared to elderly.
To gain semi-quantitative information, peak areas in the original
spectra were integrated for these three metabolites and differences
with statistical significance were confirmed by using Wilcoxon
Rank Sum test (Figure 4, Table S11). Lastly, we have reported
values for three metabolites of interests in urine in females and
males individuals, displaying no gender differences for PAG, PCS,
2-HB (Tables S12, S13).
Discussion
In the present study we have characterized for the first time, by
using a complementary NMR and MS-based metabonomics and
lipidomic approach, in both serum and urine, the metabolic
phenotype (metabotype) of extreme longevity in a representative
Northern Italian population composed mostly by female individ-
uals. While the young individuals are limited in numbers they
serve, from an observational point of view, as a representative
aging group to distinguish specific metabolic changes delayed or
preserved during the ageing of centenarians, from metabolic
features that are either a continuation of normal ageing or
indicative of a drift in the ageing processes. Comprehensive MS-
based targeted metabonomics serum analysis revealed important
biological changes associated to aging (Fig. 1, Table S3). Among
these changes we reveal an age-related reduction of Tryptophan
(Trp) concentration, supporting the proposed link among its
decreased level and the raise of chronic low-grade inflammatory
conditions [22].Several studies found patients with inflammatory
diseases to have significant elevations in serum kynurenine and
depletion of Trp compared to control population [23]. Recent
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work also displayed the relationship between reduced serum Trp
and increase immune activation [24]. With increasing age we
observed lower concentration of lysophospatidylcholines (LPC
18:2, LPC 20:4). While LPCs exhibit different physical and
biological properties based on fatty acid chain length and degree of
unsaturation, phospholipids are inflammatory mediators [25], with
atherogenic properties [26] and their altered levels are linked to
age-related physiological changes [27]. Lastly, with increasing age
we found an increase in SM 24:1 and SM 16:0. Consistent with
our findings, alteration of plasma lipid profiles were previously
observed in different aging and caloric restriction animal models
[11,28].
Interestingly, the metabolic differences seen in the elderly
cohort support the notion that siblings of longevity parents have a
distinctive aging metabolic phenotype from their age matched
controls [29] (Figure 3, Table S9). While the exact biological
significance of the noted LPCs and amino acids changes, and how
these might be related to longer life expectancy and/or delay in
age-related diseases, are not clear at the moment, and worth
further investigation, it is crucial to denote that serine is needed for
Figure 1. Metabolic signature of aging and longevity in serum. Targeted LC/MS metabonomics on the aging cohort (young, elderly, and
centenarians) revealed three trends within the identified markers. (A) Set of metabolites that decreased/increased within age. (B) Set of metabolites
that deceased or increased in centenarians only. (C) Set of metabolites maintained at similar concentration level in centenarians and young people
but not in the elderly. Reported is median value in mM among the three age groups. Blue denotes negative/decreased concentration, orange denotes
positive/increased correlation, black denotes no changes. All significantly regulated metabolites are listed in Table S3.
doi:10.1371/journal.pone.0056564.g001
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the metabolism of fats and fatty acids, muscle growth, and to
maintain a healthy immune system and was previously found to
decrease in plasma under inflammatory conditions [30], while
phenylalanine exhibits anti-inflammatory properties and it is often
used to treat arthritis and Parkinson’s disease [31].
Further, our study reveals that longevity can be ascribed as a
distinct metabolic phenotype marked by specific changes in serum
lipid profile (Fig. 1A, 1C, Table S3). Centenarians are character-
ized by decreased concentrations of the sphingomyeline SM 24:0
and SM-OH 22:1, and the diacylphosphatidylcholine PC 36:2.
SMs species are important cellular membrane constituents which
are tightly associated with cholesterol in construction, metabolism
and transport, and which are enriched in lipid rafts. The
physiological role of SM is still unclear and previous studies
report diverging hypothesis on their relationship with cardiovas-
cular risk conditions [32,33]. Centenarians exhibited also specific
monotonic changes in concentration of LPC 18:0, while varying in
concentrations of several acyl-ether, PC-O species (decreased PC-
O 34:3, PC-O 36:4, PC-O 40:1, and increased PC-O 32:1, PC-O
34:1). Plasmalogens containing a vinyl ether bond link to the sn-1
aliphatic chain of the glycerol backbone are endogenous
antioxidant. Several studies have indicated that plasmalogens are
Figure 2. Metabolic signature of aging and longevity in serum as per LC/MS eicosanoids profiling. Reported is median value in ng/
100 ml serum among the three age groups. Blue denotes negative/decreased concentration, orange denotes positive/increased correlation, black
denotes no changes. All significantly regulated metabolites are listed in Table S6.
doi:10.1371/journal.pone.0056564.g002
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depleted in a number of human pathologies with their levels
changing in response to oxidative damage [34].
We also uncovered a set of compounds remarkably similar in
circulating levels among young subjects and centenarians, while
varying in the elderly only, characterized by an increased
concentration of specific glycerophospholipids mostly polyunsatu-
rated diacyl phospholipids (PC) (Fig. 2C, Table S3). PC is a major
structural lipid of the cell membrane and it is involved in lipid
metabolism being crucial for lipid transport. Interestingly,
increased concentrations of plasma polyunsaturated fatty acids
have been implicated in the pathogenesis of chronic diseases [35].
At the moment we do not know how modification of cell
membrane lipid composition leads to functional changes in
longevity metabolic processes, including response to chronic
diseases. If replicated in larger studies, the altered metabolites
might be considered as potential biomarkers in the generation of
new hypotheses on the biological mechanisms behind longevity.
Yet, although our observational data cannot drive any concluding
statements on the possible causality linkage between inflammatory
status, aging, and modulation of lipid metabolism, it is nowadays
well accepted that the down-regulation of the mammalian target of
rapamycin (mTOR) signaling pathway is a central regulatory
process of pro-longevity in mammals [36]. The mTOR encom-
passes a series of regulatory multi-protein complexes from the the
kinase family involved in cellular response to multiple triggers
including nutrients, and reactive oxygen species (ROS), and
trough the mTORcomplex 1 (mTORC1) possibly controlling lipid
biosynthesis [37]. The down-regulation of this pathway has
Figure 3. Differences in metabolic profiles as displayed by LC/MS-MS targeted approach between centenarian’s offspring (46
subjects average age 68.4 yrs) and offspring of non long-lived parents (42 subjects average age 70.7 yrs). Bar plots indicating mean
(mM) 6standard error. All significantly regulated metabolites and statistical changes are listed in Table S9. Significant differences were assessed by
Mann-Whitney U test where *p,0.05., **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0056564.g003
Figure 4. Markers of longevity as per 1H-NMR urine profiling. Bar plots indicating mean (relative concentration) 6standard error.
PAG=Phenylacetylglutamine, PCS= p-cresol-sulfate, 2HB= 2-hydroxybenzoate. All significantly regulated metabolites and statistical changes are
listed in Table S12. Significant differences were assessed by Mann-Whitney U test where ***p,0.001.
doi:10.1371/journal.pone.0056564.g004
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resulted in observing an extension of lifespan in multiple organisms
[38]. The regulation of mTOR also cross-talks with AMP-
activated kinase, Sirt1, and Insulin/IGF-1 in a concerted manner
that points to consider this complex network as a model of
longevity [39]. The down-regulation of mTOR can activate Sirt1
and the AMPK pathways, and expression of specific mitochondrial
genes and fatty acid oxidation. One could hypothesize that the
downstream effect of these complex intracellular processes would
lead to the expression of a specific blood lipid profile with a
plausible remodeling on the composition of phospho/sphingolipids
and lipoprotein particles specific to the centenarian phenotype.
Indeed correlation analyses (Table S14) display that the LDL
concentration is correlated to specific SMs (SM 16:0 r2 = 0.34,
SM-OH 22:1 r2 = 0.40, SM 24:0 r2 = 0.39), while PC-O species
(PC:O 34:3 r2 = 0.57, PC:O 38:0 r2 = 0.38, PC:O 38:6 r2 = 0.39)
are positively correlated to the HDL circulating level, a feature
previously reported for ageing [40]. Thus it appears also that the
displayed differences in concentration levels of PC-O species in
centenarians might be due to variation in coping ROS, while
supporting their role as serum antioxidants preventing lipoprotein
oxidation.
Furthermore, we depicted specific changes in the longevity
phenotype in arachidonic acid synthesis (Fig. 2, Table S6), key
mediator of immune and inflammatory reactions. Here we
discerned higher concentration of leukotriene 4 (LTE-4), which
plays a pivotal role in allergic and inflammatory diseases, causing
increased vascular permeability and vasodilatation [41]. Cente-
narians displayed higher circulating levels of 15-hydroxy-eicosate-
traenoic acid (15-HETE), a major product of 15-lipoxygenase (15-
LOX) enzyme, known for its anti-inflammatory properties [42].
Increased activation of cytochrome P450 pathway in centenarians
is further supported by increased circulating levels of 8,9-
epoxyeicosatrienoic (8,9-EpETrE) and decreased concentration
of 11,12-dihydroxy-eicosatrienoic acid (11,12-DiHETrE). EpE-
TrE are important components of many intracellular signaling in
both cardiac and extracardiac tissues [43]. EETs display anti-
inflammatory effects by inhibiting nuclear factor kappa B (NF-kB)-
mediated gene transcription [43,44]. EpETrEs can be further
metabolized by soluble epoxide hydrolase (sEH) to dihydroxy-
eicosatrienoic acids (DiHETrE), reducing their original biological
activity. Therefore, the decreased concentration of 11,12-DiHE-
TrE might reveal decreased sEH’s effect on its precursor 11,12-
EpETrE. Most important, centenarians displayed lower circulat-
ing levels of 9-hydroxy-octadecadienoic acid (9-HODE), a
biological active molecule, marker of lipid peroxidation, and in
9-oxo-octadecadienoic acid (9-oxo-HODE), a stable oxidation
product of linoleic acid, the generations of which is increased with
increasing oxidative stress [45]. Previous studies determined the
positive relationship among lower 9-HODE concentrations and
Mediterranean diet to reduced cardiovascular disease risk [46],
and our results might underpin this trend, while at the same time
revealing decreased oxidative damage in centenarians. Increased
levels of lipid oxidation products such as 9-oxoODE are normally
detected in plasma samples of patients suffering rheumatoid
arthritis [47], and arthrosclerosis [48]. Interestingly, regulatory
process involving activation of cellular detoxification, through the
nuclear erythroid 2-related factor (Nrf2) signaling pathway, is also
being proposed as an element of increased lifespan [49]. Our
findings on the increased concentration of 8,9-EpETrE, suggesting
increased activity of CYP enzyme, would support promotion of
Figure 5. Spearman correlation map between urine markers of longevity (PAG=phenylacetylglutamine, PCS=p-cresol sulfate, 3-
HB=3-hydroxybenzoate) and order/genus-like bacterial phylogroups. Blue denotes negative correlation, orange denotes positive
correlation, and black denotes no correlation.
doi:10.1371/journal.pone.0056564.g005
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cellular detoxification mechanisms through specific modulation of
the arachidonic acid metabolic cascade in centenarians. Such
effective mechanism might results in the activation and successful
antioxidative response, as displayed by the decreased concentra-
tion of 9-HODE, and 9-oxoODE in centenarians. Compared to
elderly, centenarians also presented depletion of eicosapentanoic
acid (EPA), an omega-3 fatty acid, which can be synthesized in
humans from alpha-linoleic acid or in greater amount directly
from oily fishes. Importantly, EPA exerts anti-inflammatory effects
mostly by increasing the biosynthesis of beneficial v-3 eicosanoids,
resolvins [50].
Taken all together, we propose that the overall lipidome
changes, above elucidated, might putatively reflect centenarians’
unique capability to adapt/respond to the accumulating oxidative
and chronic inflammatory processes characteristics of their
extreme aging phenotype.
In the elderly population associations among gut microbiota
and inflammatory status had been clearly displayed [51,52]. In our
study urine metabolic profiling revealed that the longevity
phenotype is affected by significant changes in the gut microbiome
as displayed by increased excretion of PCS and PAG (Fig. 4, Table
S11) in centenarians compared to elderly. Our findings support
the initial hypothesis suggesting that late aging process might lead
to increase p-cresol production, driven by age-related changes in
the composition of the gut bacteria [53]. Gut microbiota
extensively catabolized protein and aromatic amino acids,
including phenylalanine and tyrosine, to form PAG and PCS
[54]. Moreover, centenarians display increased concentration of 2-
HB (Figure 4) a compound present in most fruits and vegetables,
with anti-inflammatory activity and with known capabilities to
inhibit transcription of cyclooxygenase-2, an enzyme that catalyses
the formation of prostaglandins during inflammation [55]. Lastly,
we assessed the relationships between urine metabotypes and
microbiota composition correlating the three markers of longevity
(PAG, PCS, 2-HB) with phylogenetic bacterial groups (Fig. 5).
PAG displays positive correlation with Proteobacteria species,
namely Campylobacter, E. coli, Haemophilus, Pseudomonas, Serratia,
Yersinia et rel, while both PCS and PAG correlating to Vibrio.
Although it has been reported that some species of Clostridia
produce phenol and p-cresol together with ammonia and
hydrogen by anaerobic degradation of aromatic amino acids
[56], our data suggest that Proteobacteria might also contribute to
the pool of PAG and PCS. Previous studies have shown that E. coli
isolated from Crohn’s Disease patients have pathogen-like
behavior in vitro, and may play a role in the inflammatory
process [57]. Of particular interest is the negative correlation of
PAG and PCS with several butyrate-producing bacteria belonging
to Clostridium cluster XIVa species, namely Butyrivibrio crossotus et
rel., E. hallii, E. rectale, E. ventriosum, F. prausnitzii, Roseburia intestinalis
as it is demonstrated that butyrate, a short chain fatty acid mainly
produced in the gut by Firmicutes of Clostridium clusters IV and
XIVa, has a protective role against chronic inflammatory diseases
[58]. Of interest is also the positive correlation of 2-HB with Proteus
et. rel. Taken together these data display that the longevity process
deeply affects the structure and composition of the human gut
microbiota, with centenarians displaying lower contribution of
Clostridium cluster XIVa, and relatives symbiotic species with
reported anti-inflammatory properties, and relative increase of
facultative anaerobes including Proteobacteria [16].
It is imperative to note that while this study portrays a sampling
representative of a limited geographic area (northern Italy), where
dietary and lifestyle factors can be assumed similar, our newly
reported longevity metabolic footprint needs further validation
across populations with different genetic backgrounds, environ-
mental conditions, and increased representation of both the
genders. While it is difficult to recruit a larger number of male
centenarians, due to significant acknowledged differences in male
to females ratio distribution in the north of Italy [12], we have
reported values for selected metabolites after gender separation
which provides a first insight into the displayed metabolites of
interest. Here, whilst the displayed metabolic differences of
longevity are maintained, after gender separation, our findings
will be compared and validated in much bigger cohorts to provide
future predictive utility, such as the ongoing EU Mark-Age
(http:// edukon.biologie.uni-konstanz.de/mark-age). Further fu-
ture studies will also have to address how nutritional challenges
and different dietary regimes in human aging populations impact
these biomarkers confirming the observed changes in the discussed
metabolic pathways.
In conclusion, our study contributes to shed light onto the
complex mosaic of human aging and longevity providing
comprehensive metabolic outcomes in biofluids that can be
paralleled with the currently investigated mechanistic routes of
the mTOR, AMPK, inflammation, and changes in the gut
microbiota, underlining the expression of human longevity
phenotype. As centenarians well represent the model of healthy
and successful aging, there are many important implications in
understanding the underlying molecular mechanisms behind such
acquired longevity and how environmental factors and nutrition
might aid in shaping such acquired successful metabolic pheno-
type.
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